Information
OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeut...
Original sourceAI Summary
Barinthus prioritizes VTP-1000 for celiac disease, Phase 1 data due mid-2025. Development of VTP-300 for hepatitis B on hold until a partner is found. Company reduces workforce by 65% to extend cash runway to 2027. U.K. operations to close; focus shifts to U.S. site in Germantown, Maryland. Financial stability supported by $112 million cash reserves as of December 2024.
Sentiment Rationale
The focus on VTP-1000 in celiac disease could enhance market value, similar to Gilead's HBV successes.
Trading Thesis
Long-term potential growth expected if VTP-1000 trials succeed, paralleling past biotech success stories.
Market-Moving
- Barinthus prioritizes VTP-1000 for celiac disease, Phase 1 data due mid-2025.
- Development of VTP-300 for hepatitis B on hold until a partner is found.
- Company reduces workforce by 65% to extend cash runway to 2027.
Key Facts
- Barinthus prioritizes VTP-1000 for celiac disease, Phase 1 data due mid-2025.
- Development of VTP-300 for hepatitis B on hold until a partner is found.
- Company reduces workforce by 65% to extend cash runway to 2027.
- U.K. operations to close; focus shifts to U.S. site in Germantown, Maryland.
- Financial stability supported by $112 million cash reserves as of December 2024.
Companies Mentioned
- GILD (GILD)
- AMGN (AMGN)
- JNJ (JNJ)
Corporate Developments
The article outlines strategic shifts that could significantly enhance BRNS's market position.